Enliven Therapeutics, Inc.
enliventherapeutics.comWhat Do They Do?
Develops small-molecule drug candidates for people with chronic myeloid leukemia and other diseases, including Graves’ disease.
10-K for FY2025, filed Mar 3, 2026We are a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people…View ↗
ELVN-001 is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region –…View ↗
We believe that our development approach, which is rooted in validated biology and differentiated chemistry, enables us to design and…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 5, 2026
−$32.5MView ↗
- ▲ +28% (Loss)
- vs −$25.3M in Q2 FY2025
From hemoglobin disorders to cancer drug development
The older report centered on tovinontrine for hemoglobin disorders, including sickle cell disease and beta-thalassemia. The latest report focuses on a small-molecule candidate for chronic myeloid leukemia and other research programs.
10-K for FY2022, filed Feb 10, 2023 10-K for FY2025, filed Mar 3, 2026Prior to the April 2022 discontinuation of our clinical programs, our business focused on developing and commercializing novel therapeutics…View ↗
We conducted the Ardent Phase 2b clinical trial of tovinontrine, a randomized, double-blind, placebo-controlled trial in approximately 115…View ↗
We also conducted the Forte Phase 2b clinical trial of tovinontrine, a randomized, double-blind, placebo-controlled trial in approximately…View ↗
Who Do They Compete With?
Competes with Novartis, Bristol Myers Squibb, Pfizer, Takeda, Ascentage Pharma, Terns Pharmaceuticals, and TargetRx
10-K for FY2025, filed Mar 3, 2026There are currently six BCR-ABL TKIs FDA approved for use in CML: Novartis AG’s Gleevec (imatinib), Tasigna (nilotinib), and Scemblix…View ↗
Loading...
